Shenzhen Zigzag Biotechnology

Shenzhen Zigzag Biotechnology is a Chinese biopharmaceutical company focused on the discovery and development of innovative small molecule and peptide therapeutics for metabolic diseases. The company leverages advanced structure-based drug design and computational chemistry to target G protein-coupled receptors (GPCRs) involved in glucose regulation and weight management. Their primary research focus includes next-generation GLP-1 and GIP receptor agonists aimed at treating type 2 diabetes and obesity with improved oral bioavailability. Zigzag Biotechnology aims to address unmet medical needs in the metabolic space through highly selective and potent molecular candidates.